Luxembourg Cohort

Title of the cohort
Luxembourg Cohort
Acronym for cohort
Lux.Cohort
Name of Principal Investigator

Title Doctor
First name  Sophie
Last name COUFFIGNAL

Address of institution where award is held

Institution
Street Address 1 A-B rue Thomas Edison
City STRASSEN
Postcode L-1445

Country
Luxembourg
Website
www.crp-sante.lu
Contact email
[email protected]
Funding source
Ministry of Research
Ministry of Health
Biobank
1. The cohort includes, or expects to include, incidence of the following conditions

  • Parkinson’s disease
  • Neurodegenerative disease in general

When studies on the above condition(s) are expected to become possible
2011 – 2015
2a. Stated aim of the cohort
To study particularly mechanism of development of parkinson disease, diabetes and lung cancer, for propose method of pre-diagnosis, and personalised medicine
2b. Features distinguishing this cohort from other population cohorts
this cohort will be built from EHES cross sectional survey, and with volonteers.

research in proteomics and metalobomics are priorities
3a. i) Number of publications that involve use of cohort to date
0
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

3b. Publication list/link to where data or publications are accessible (if available)

3c. Information (i.e. research findings) expected to be gained from the population cohort

4a. Study criteria: age range of participants at recruitment

Age in years from: 18 years
To (‘until death’ if applicable): 75 years

4b. Study criteria: inclusion criteria
people with parkinson diseases
people with diabetes
people with cancer
people who participate in EHES cross sectional study
4c. Study criteria: exclusion criteria
institutionalised people
5. Size of the cohort (i.e. number of participants enrolled)
More than 15,000
6a. Measures used to characterise participants
age, gender, ethnical informations, socio economic conditions, educational conditions, diseases and medications, family diseases, lifestyle (tobacco, alcoohol, physical activity, nutrition), work situation, environmental conditions, health status, health care using, cognitiv assessement, anthropometric measures, blood pressure, biological analysis, genetic informations
6b. Additional measures for participants with a clinical disorder
if diabetes, more blood analysis and family disease if parkinson, more blood analysis, some neurological tests, family disease
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
No
7. Study design
Prospective cohort
8. Cases matched by

  • Age
  • Sex
  • Co-morbidities
  • Cognitive function
  • Physical ability

9a. Does the study include a specialised subset of control participants
No
9b. If yes, description of specialised subset of control participants

10a. i) Data collection start date
01-01-2012
10a. ii) Data collection end date
31-12-2017
10a iii) Data collection for this study is
At the planning stage
10b. Plans to continue the cohort study beyond the current projected end date

  • Yes – intend to apply for funding

11. Data collected

  • Only through the study
  • Through links to medical records

12. System in place to enable re-contact with patients for future studies
Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)
13a. Format and availability of data stored in a database

Yes/No % available
Data summarised in database  Yes
Database is web-based  Yes
Database on spreadsheet
Database is on paper
Other (specify)

Language used:
french, german, english, portugues
13b. Format and availability of data held as individual records

Language used:

14a. Are data available to other groups
Yes
14b. Access policy/mechanisms for access if data are available to other groups

  • Access through collaboration with PI only
  • Access independent of collaboration with PI
  • Access Committee mechanism
  • National access International access
  • Access to industry
  • Access for pilot studies permitted
  • Access restricted to peer-reviewed work
  • Applicant needs to provide separate external ethics approval

15. Data sharing policy specified as a condition of use
Data made publicly available after a specified time point
16a. Are tissues/samples/DNA available to other groups
Yes
16b. i) Description of available tissues/samples/DNA

  • Living donors:blood
  • Living donors: blood derivatives
  • Living donors: DNA

16b. ii) Form available tissues/samples/DNA are supplied in

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
Yes
17. Is information on biological characteristics available to other groups

  • Yes, for all the cohort

Luxembourg Cohort

Population Cohorts
Luxembourg
Neurodegenerative disease in general|Parkinson’s disease & PD-related disorders

 

 

Post
Filter